Genmab A (GMAB) Operating Leases (2019 - 2025)

Genmab A has reported Operating Leases for 5 years, with the latest figure at $134.0 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Leases rose 2.29% year-over-year to $134.0 million; the trailing twelve-month figure through Dec 2025 stood at $134.0 million (up 2.29% YoY), and the FY2025 full-year result was $134.0 million, up 2.29% from the prior year.
• Operating Leases for Q4 2025 stood at $134.0 million, down from $143.0 million in the prior quarter.
• The five-year high for Operating Leases was $143.0 million in Q1 2025, with the low at $114.0 million in Q4 2023.
• Historically, Operating Leases has averaged $130.5 million across 3 years, with a median of $132.5 million in 2024.
• Annual changes were most pronounced in 2024 — Operating Leases climbed 14.91% — and 2025, when it climbed 2.29%.
• Genmab A's Operating Leases stood at $114.0 million in 2023, then rose by 14.91% to $131.0 million in 2024, then gained by 2.29% to $134.0 million in 2025.
• The last three Operating Leases figures came in at $134.0 million (Q4 2025), $143.0 million (Q1 2025), and $131.0 million (Q4 2024), per Business Quant data.